142 related articles for article (PubMed ID: 28955920)
1. Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique.
Ando D; Inoue M; Kamada H; Taki S; Furuya T; Abe Y; Nagano K; Tsutsumi Y; Tsunoda SI
Biochem Biophys Rep; 2016 Sep; 7():309-315. PubMed ID: 28955920
[TBL] [Abstract][Full Text] [Related]
2. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
[TBL] [Abstract][Full Text] [Related]
3. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S
Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081
[TBL] [Abstract][Full Text] [Related]
4. Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.
Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Minowa K; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Tsunoda S; Tsutsumi Y
Pharmazie; 2010 Feb; 65(2):93-6. PubMed ID: 20225650
[TBL] [Abstract][Full Text] [Related]
5. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system.
Yoshioka Y; Watanabe H; Morishige T; Yao X; Ikemizu S; Nagao C; Ahmad S; Mizuguchi K; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Biomaterials; 2010 Mar; 31(7):1935-43. PubMed ID: 19853911
[TBL] [Abstract][Full Text] [Related]
6. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.
Shibata H; Yoshioka Y; Ohkawa A; Minowa K; Mukai Y; Abe Y; Taniai M; Nomura T; Kayamuro H; Nabeshi H; Sugita T; Imai S; Nagano K; Yoshikawa T; Fujita T; Nakagawa S; Yamamoto A; Ohta T; Hayakawa T; Mayumi T; Vandenabeele P; Aggarwal BB; Nakamura T; Yamagata Y; Tsunoda S; Kamada H; Tsutsumi Y
J Biol Chem; 2008 Jan; 283(2):998-1007. PubMed ID: 18003610
[TBL] [Abstract][Full Text] [Related]
7. Generation of a sensitive TNFR2-specific murine assays system.
Ando D; Kamada H; Inoue M; Taki S; Furuya T; Abe Y; Nagano K; Tsutsumi Y; Tsunoda S
Pharmazie; 2016 May; 71(5):235-7. PubMed ID: 27348964
[TBL] [Abstract][Full Text] [Related]
8. [Development of New Biologics through Creation of a Functional Cytokine Mutant].
Kamada H
Yakugaku Zasshi; 2015; 135(7):843-9. PubMed ID: 26135083
[TBL] [Abstract][Full Text] [Related]
9. [Creation of TNFR1-selective antagonist and its therapeutic effects].
Nomura T; Abe Y; Yoshioka Y; Nakagawa S; Tsunoda S; Tsutsumi Y
Yakugaku Zasshi; 2010 Jan; 130(1):63-8. PubMed ID: 20046067
[TBL] [Abstract][Full Text] [Related]
10. Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.
Nomura T; Abe Y; Kamada H; Inoue M; Kawara T; Arita S; Furuya T; Yoshioka Y; Shibata H; Kayamuro H; Yamashita T; Nagano K; Yoshikawa T; Mukai Y; Nakagawa S; Taniai M; Ohta T; Tsunoda S; Tsutsumi Y
Biochem Biophys Res Commun; 2009 Oct; 388(4):667-71. PubMed ID: 19682974
[TBL] [Abstract][Full Text] [Related]
11. Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways.
Jupp OJ; McFarlane SM; Anderson HM; Littlejohn AF; Mohamed AA; MacKay RH; Vandenabeele P; MacEwan DJ
Biochem J; 2001 Nov; 359(Pt 3):525-35. PubMed ID: 11672426
[TBL] [Abstract][Full Text] [Related]
12. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
Shibata H; Abe Y; Yoshioka Y; Nomura T; Sato M; Kayamuro H; Kawara T; Arita S; Furuya T; Nagano K; Yoshikawa T; Kamada H; Tsunoda S; Tsutsumi Y
Cytokine; 2010 Apr; 50(1):75-83. PubMed ID: 20045350
[TBL] [Abstract][Full Text] [Related]
13. Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein.
Padutsch T; Sendetski M; Huber C; Peters N; Pfizenmaier K; Bethea JR; Kontermann RE; Fischer R
Front Pharmacol; 2019; 10():1490. PubMed ID: 31920671
[TBL] [Abstract][Full Text] [Related]
14. Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy.
Morishige T; Yoshioka Y; Narimatsu S; Ikemizu S; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Cytokine; 2013 Feb; 61(2):578-84. PubMed ID: 23246116
[TBL] [Abstract][Full Text] [Related]
15. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a TNFR2-Selective Agonistic TNF-α Mutant and Its Derivatives as an Optimal Regulatory T Cell Expander.
Inoue M; Yamashita K; Tsuji Y; Miki M; Amano S; Okumura T; Kuge K; Tone T; Enomoto S; Yoshimine C; Morita Y; Ando D; Kamada H; Mikami N; Tsutsumi Y; Tsunoda SI
J Immunol; 2021 Apr; 206(8):1740-1751. PubMed ID: 33782090
[TBL] [Abstract][Full Text] [Related]
17. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis.
Guo G; Morrissey J; McCracken R; Tolley T; Liapis H; Klahr S
Am J Physiol Renal Physiol; 2001 May; 280(5):F777-85. PubMed ID: 11292619
[TBL] [Abstract][Full Text] [Related]
18. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy.
Guo G; Morrissey J; McCracken R; Tolley T; Klahr S
Am J Physiol; 1999 Nov; 277(5):F766-72. PubMed ID: 10564241
[TBL] [Abstract][Full Text] [Related]
19. Lack of Evidence for a Direct Interaction of Progranulin and Tumor Necrosis Factor Receptor-1 and Tumor Necrosis Factor Receptor-2 From Cellular Binding Studies.
Lang I; Füllsack S; Wajant H
Front Immunol; 2018; 9():793. PubMed ID: 29740434
[TBL] [Abstract][Full Text] [Related]
20. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.
Dong Y; Fischer R; Naudé PJ; Maier O; Nyakas C; Duffey M; Van der Zee EA; Dekens D; Douwenga W; Herrmann A; Guenzi E; Kontermann RE; Pfizenmaier K; Eisel UL
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12304-12309. PubMed ID: 27791020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
